Recent advances of benzimidazole as anticancer agents.
PARP
androgen receptor
benzimidazole
cancer targets
topoisomerase
tubulin inhibitors
tyrosine kinase
Journal
Chemical biology & drug design
ISSN: 1747-0285
Titre abrégé: Chem Biol Drug Des
Pays: England
ID NLM: 101262549
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
20
02
2023
received:
31
10
2022
accepted:
14
03
2023
medline:
17
7
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
Cancer is the second leading cause of death globally, with 9.6 million deaths yearly. As a life-threatening disease, it necessitates the emergence of new therapies. Resistance to current chemotherapies drives scientists to develop new medications that will eventually be accessible. Because heterocycles are so common in biological substances, compounds play a big part in the variety of medications that have been developed. The "Master Key" is the benzimidazole nucleus, which consists of a six-membered benzene ring fused with a five-membered imidazole/imidazoline ring, which is an azapyrrole. One of the five-membered aromatic nitrogen heterocycles identified in American therapies that have been approved by the Food and Drug Administration (FDA). Our results show that benzimidazole's broad therapeutic spectrum is due to its structural isosteres with purine, which improves hydrogen bonding, electrostatic interactions with topoisomerase complexes, intercalation with DNA, and other functions. It also enhances protein and nucleic acid inhibition, tubulin microtubule degeneration, apoptosis, DNA fragmentation, and other functions. Additionally, readers for designing the more recent benzimidazole analogues as prospective cancer treatments.
Substances chimiques
Antineoplastic Agents
0
Pharmaceutical Preparations
0
Benzimidazoles
0
DNA
9007-49-2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
357-376Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Acar Çevik, U., Sağlık, B. N., Osmaniye, D., Levent, S., Kaya Çavuşoğlu, B., Karaduman, A. B., Atlı Eklioğlu, Ö., Özkay, Y., & Kaplancıklı, Z. A. (2020). Synthesis, anticancer evaluation and molecular docking studies of new benzimidazole-1, 3, 4-oxadiazole derivatives as human topoisomerase types I poison. Journal of Enzyme Inhibition and Medicinal Chemistry, 35(1), 1657-1673.
Akhtar, W., Khan, M. F., Verma, G., Shaquiquzzaman, M., Rizvi, M. A., Mehdi, S. H., Akhter, M., & Alam, M. M. (2017). Therapeutic evolution of benzimidazole derivatives in the last quinquennial period. European Journal of Medicinal Chemistry, 126, 705-753.
Aragón-Muriel, A., Liscano, Y., Upegui, Y., Robledo, S. M., Ramírez-Apan, M. T., Morales-Morales, D., Oñate-Garzón, J., & Polo-Cerón, D. (2021). In vitro evaluation of the potential pharmacological activity and molecular targets of new benzimidazole-based schiff base metal complexes. Antibiotics, 10(6), 728.
Arita, T., Morimoto, M., Yamamoto, Y., Miyashita, H., Kitazawa, S., Hirayama, T., Sakamoto, S., Miyamoto, K., Adachi, R., Iwatani, M., & Hara, T. (2017). Prolyl-tRNA synthetase inhibition promotes cell death in SK-MEL-2 cells through GCN2-ATF4 pathway activation. Biochemical and Biophysical Research Communications, 488(4), 648-654.
Bansal, S., Sur, S., & Tandon, V. (2018). Benzimidazoles: Selective inhibitors of topoisomerase I with differential modes of action. Biochemistry, 58(6), 809-817.
Bansal, Y., Minhas, R., Singhal, A., Arora, R. K., & Bansal, G. (2021). Benzimidazole: A multifacted nucelus for anticancer agents. Current Organic Chemistry, 25(6), 669-694.
Bansal, Y., & Silakari, O. (2012). The therapeutic journey of benzimidazoles: A review. Bioorganic & Medicinal Chemistry, 20(21), 6208-6236.
Barot, K. P., Nikolova, S., Ivanov, I., & Ghate, M. D. (2013). Novel research strategies of benzimidazole derivatives: A review. Mini Reviews in Medicinal Chemistry, 13(10), 1421-1447.
Bianco, R., Gelardi, T., Damiano, V., Ciardiello, F., & Tortora, G. (2007). Rational bases for the development of EGFR inhibitors for cancer treatment. The International Journal of Biochemistry & Cell Biology, 39(7-8), 1416-1431.
Bommhardt, U., Schraven, B., & Simeoni, L. (2019). Beyond TCR signaling: Emerging functions of Lck in cancer and immunotherapy. International Journal of Molecular Sciences, 20(14), 3500.
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424.
Class, I., & USPC, A. B. (2014). Inventors: Jonathan S. Lindsey (Raleigh, NC, US) Michael Krayer (Raleigh, NC, US) assignees. North Caroliina State University.
Cosenza, M., & Pozzi, S. (2018). The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease. International Journal of Molecular Sciences, 19(8), 2337.
Delgado, J. L., Hsieh, C. M., Chan, N. L., & Hiasa, H. (2018). Topoisomerases as anticancer targets. Biochemical Journal, 475(2), 373-398.
Elancheran, R., Saravanan, K., Choudhury, B., Divakar, S., Kabilan, S., Ramanathan, M., das, B., Devi, R., & Kotoky, J. (2016). Design and development of oxobenzimidazoles as novel androgen receptor antagonists. Medicinal Chemistry Research, 25(4), 539-552.
Faheem, M., Rathaur, A., Pandey, A., Kumar Singh, V., & Tiwari, A. K. (2020). A review on the modern synthetic approach of benzimidazole candidate. ChemistrySelect, 5(13), 3981-3994.
Fang, X.-J., Jeyakkumar, P., Avula, S. R., Zhou, Q., & Zhou, C. H. (2016). Design, synthesis and biological evaluation of 5-fluorouracil-derived benzimidazoles as novel type of potential antimicrobial agents. Bioorganic & Medicinal Chemistry Letters, 26(11), 2584-2588.
Ferreira, R., Schneekloth, J. S., Jr., Panov, K. I., Hannan, K. M., & Hannan, R. D. (2020). Targeting the RNA polymerase I transcription for cancer therapy comes of age. Cell, 9(2), 266.
Fioretti, F., Sita-Lumsden, A., Bevan, C. L., & Brooke, G. N. (2014). Revising the role of the androgen receptor in breast cancer. Journal of Molecular Endocrinology, 52(3), R257-R265.
Ganapathi, R., & Ganapathi, M. K. (2013). Mechanisms regulating resistance to inhibitors of topoisomerase II. Frontiers in Pharmacology, 4, 89.
Ganguly, S. S., & Plattner, R. (2012). Activation of abl family kinases in solid tumors. Genes & Cancer, 3(5-6), 414-425.
Guo, C., Pairish, M., Linton, A., Kephart, S., Ornelas, M., Nagata, A., Burke, B., Dong, L., Engebretsen, J., & Fanjul, A. N. (2012). Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists. Bioorganic & Medicinal Chemistry Letters, 22(7), 2572-2578.
Haddach, M. (2017). Compositions, uses and methods for making them. Google Patents.
Hajba, L., & Guttman, A. (2014). Circulating tumor-cell detection and capture using microfluidic devices. TrAC Trends in Analytical Chemistry, 59, 9-16.
Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31-46.
Helsen, C., Van den Broeck, T., Voet, A., Prekovic, S., Van Poppel, H., Joniau, S., & Claessens, F. (2014). Androgen receptor antagonists for prostate cancer therapy. Endocrine-Related Cancer, 21(4), T105-T118.
Howlader, N. N. A., Krapcho, M., Garshell, J., Miller, D., Altekruse, S. F., Kosary, C. L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D. R., Chen, H. S., Feuer, E. J., & Cronin, K. A. (2015). SEER cancer statistics review, 1975-2012. National Cancer Institute.
Hu, W., Huang, X. S., Wu, J. F., Yang, L., Zheng, Y. T., Shen, Y. M., Li, Z. Y., & Li, X. (2018). Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches. Journal of Medicinal Chemistry, 61(20), 8947-8980.
Huang, X., Huang, R., Gou, S., Wang, Z., Liao, Z., & Wang, H. (2017). Platinum (IV) complexes conjugated with phenstatin analogue as inhibitors of microtubule polymerization and reverser of multidrug resistance. Bioorganic & Medicinal Chemistry, 25(17), 4686-4700.
Issar, U., Arora, R., Kumari, T., & Kakkar, R. (2019). Combined pharmacophore-guided 3D-QSAR, molecular docking, and virtual screening on bis-benzimidazoles and ter-benzimidazoles as DNA-topoisomerase I poisons. Structural Chemistry, 30(4), 1185-1201.
Jones, P., Wilcoxen, K., Rowley, M., & Toniatti, C. (2015). Niraparib: A poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of tumors with defective homologous recombination. ACS Publications.
Kaliraj, S., & Kathiravan, M. K. (2020). Synthesis and cytotoxic evaluation of novel benzimidazole fused condensed thienopyrimdines derivatives. Current Bioactive Compounds, 16(2), 133-141.
Kandil, S., Lee, K. Y., Davies, L., Rizzo, S. A., Dart, D. A., & Westwell, A. D. (2019). Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists. European Journal of Medicinal Chemistry, 167, 49-60.
Kenny, R. G., Ude, Z., Docherty, J. R., & Marmion, C. J. (2020). Vorinostat and Belinostat, hydroxamate-based anti-cancer agents, are nitric oxide donors. Journal of Inorganic Biochemistry, 206, 110981.
Keri, R. S., Adimule, V., Kendrekar, P., & Sasidhar, B. S. (2022). The nano-based catalyst for the synthesis of benzimidazoles. Topics in Catalysis, 65, 1-21.
Kingston, D. G. (2009). Tubulin-interactive natural products as anticancer agents. Journal of Natural Products, 72(3), 507-515.
Law, C. S., & Yeong, K. Y. (2021). Benzimidazoles in drug discovery: A patent review. ChemMedChem, 16(12), 1861-1877.
Lenz, H.-J. (2006). Anti-EGFR mechanism of action: Antitumor effect and underlying cause of adverse events. Oncology (Williston Park, NY), 20(5 Suppl 2), 5-13.
Li, F.-R., Li, Q., Zhou, H. X., Qi, H., & Deng, C. Y. (2013). Detection of circulating tumor cells in breast cancer with a refined immunomagnetic nanoparticle enriched assay and nested-RT-PCR. Nanomedicine: Nanotechnology, Biology and Medicine, 9(7), 1106-1113.
Li, T., Zhang, C., Hassan, S., Liu, X., Song, F., Chen, K., Zhang, W., & Yang, J. (2018). Histone deacetylase 6 in cancer. Journal of Hematology & Oncology, 11(1), 1-10.
Liao, B.-C., Lin, C.-C., & Yang, J. C.-H. (2015). Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Current Opinion in Oncology, 27(2), 94-101.
Liu, H.-K., & Sadler, P. J. (2011). Metal complexes as DNA intercalators. Accounts of Chemical Research, 44(5), 349-359.
Malyuchenko, N. V., Kotova, E. Y., Kulaeva, O. I., Kirpichnikov, M. P., & Studitskiy, V. M. (2015). PARP1 inhibitors: Antitumor drug design. Acta Naturae (англоязычная версия), 7(3 (26)), 27-37.
Miao, T.-T., Tao, X. B., Li, D. D., Chen, H., Jin, X. Y., Geng, Y., Wang, S. F., & Gu, W. (2018). Synthesis and biological evaluation of 2-aryl-benzimidazole derivatives of dehydroabietic acid as novel tubulin polymerization inhibitors. RSC Advances, 8(31), 17511-17526.
Narayanan, R., Miller, D. D., Ponnusamy, T., Hwang, D.-J., Duke, C. B., Coss, C. C., Jones, A., & Dalton, J. T. (2018). Selective androgen receptor degrader (SARD) ligands and methods of use thereof. Google Patents.
Nath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020). Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects. Life Sciences, 258, 118189.
Park, J. S., Yoon, Y. J., Cho, M. J., Lee, H. B., Yoo, J. K., & Lee, B. Y. (2018). Heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same. Google Patents.
Peto, C. J., Jablons, D., & Lemjabbar-Alaoui, H. (2020). Anti-cancer compounds. Google Patents.
Pinto-Díez, C., Ferreras-Martín, R., Carrión-Marchante, R., González, V. M., & Martín, M. E. (2020). Deeping in the role of the MAP-kinases interacting kinases (MNKs) in cancer. International Journal of Molecular Sciences, 21(8), 2967.
Prabhu, S. A., Moussa, O., Miller, W. H., Jr., & del Rincón, S. V. (2020). The MNK1/2-eIF4E axis as a potential therapeutic target in melanoma. International Journal of Molecular Sciences, 21(11), 4055.
Prota, A. E., Bargsten, K., Zurwerra, D., Field, J. J., Díaz, J. F., Altmann, K. H., & Steinmetz, M. O. (2013). Molecular mechanism of action of microtubule-stabilizing anticancer agents. Science, 339(6119), 587-590.
Purushottamachar, P., Ramalingam, S., & Njar, V. C. (2019). Development of benzimidazole compounds for cancer therapy. Chemistry and Applications of Benzimidazole and its Derivatives, 1, 1-15.
Qian, D., Han, A. Q., Hamilton, M., & Wang, E. (2011). Phosphatidylinositol 3 kinase inhibitors. Google Patents.
Qin, G., Li, Y., Xu, X., Wang, X., Zhang, K., Tang, Y., Qiu, H., Shi, D., Zhang, C., Long, Q., Lee, K., Zhai, Q., Wang, S., Chen, M., & Deng, W. (2019). Panobinostat (LBH589) inhibits Wnt/β-catenin signaling pathway via upregulating APCL expression in breast cancer. Cellular Signalling, 59, 62-75.
Qiu, W., Lam, R., Voytyuk, O., Romanov, V., Gordon, R., Gebremeskel, S., Vodsedalek, J., Thompson, C., Beletskaya, I., Battaile, K. P., Pai, E. F., Rottapel, R., & Chirgadze, N. Y. (2014). Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2. Acta Crystallographica Section D: Biological Crystallography, 70(10), 2740-2753.
Radhamanalan, R., Alagumuthu, M., & Nagaraju, N. (2018). Synthesis and drug efficacy validations of racemic-substituted benzimidazoles as antiulcer/antigastric secretion agents. Future Medicinal Chemistry, 10(15), 1805-1820.
Raimondi, M. V., Randazzo, O., La Franca, M., Barone, G., Vignoni, E., Rossi, D., & Collina, S. (2019). DHFR inhibitors: Reading the past for discovering novel anticancer agents. Molecules, 24(6), 1140.
Rathkopf, D., & Scher, H. I. (2013). Androgen receptor antagonists in castration-resistant prostate cancer. Cancer Journal, 19(1), 43.
Saleem, S. S., Sankarganesh, M., Jose, P. A., & Raja, J. D. (2021). Design, synthesis, antioxidant, antimicrobial, DNA binding and molecular docking studies of morpholine based Schiff base ligand and its metal (II) complexes. Inorganic Chemistry Communications, 124, 108396.
Sampson, P. B., Patel, N. K. B., Pauls, H. W., Li, S. W., Ng, G., Laufer, R., Liu, Y., Lang, Y., & University Health Network. (2019). HPK1 inhibitors and methods of using same. Google Patents.
Satija, G., Sharma, B., Madan, A., Iqubal, A., Shaquiquzzaman, M., Akhter, M., Parvez, S., Khan, M. A., & Alam, M. M. (2022). Benzimidazole based derivatives as anticancer agents: Structure activity relationship analysis for various targets. Journal of Heterocyclic Chemistry, 59(1), 22-66.
Schiltz, G. E., Izquierdo-Ferrer, J., Vagadia, P., Clutter, M. R., Mishra, R. K., & Platanias, L. C. (2018). Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2). Google Patents.
Schultz, J., Vågberg, J., Olsson, E., Färnegårdh, K., Jönsson, M., Hammer, K., & Krüger, L. (2019). Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity. Google Patents.
Shaharyar, M., Mazumder, A., & Ahsan, M. J. (2014). Synthesis, characterization and anticancer evaluation of 2-(naphthalen-1-ylmethyl/naphthalen-2-yloxymethyl)-1-[5-(substituted phenyl)-[1, 3, 4] oxadiazol-2-ylmethyl]-1H-benzimidazole. Arabian Journal of Chemistry, 7(4), 418-424.
Shan, W., Pan, Y., Fang, H., Guo, M., Nie, Z., Huang, Y., & Yao, S. (2014). An aptamer-based quartz crystal microbalance biosensor for sensitive and selective detection of leukemia cells using silver-enhanced gold nanoparticle label. Talanta, 126, 130-135.
Shrivastava, N., Naim, M. J., Alam, M. J., Nawaz, F., Ahmed, S., & Alam, O. (2017). Benzimidazole scaffold as anticancer agent: Synthetic approaches and structure-activity relationship. Archiv der Pharmazie, 350(6), e201700040.
Si, J., & Jiang, M. (2020). Urea compound, preparation method therefor and medical use thereof. Google Patents.
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics. CA: A Cancer Journal for Clinicians, 72, 7-33.
Singh, I., Luxami, V., & Paul, K. (2019). Synthesis and in vitro evaluation of naphthalimide-benzimidazole conjugates as potential antitumor agents. Organic & Biomolecular Chemistry, 17(21), 5349-5366.
Singhal, S., Khanna, P., & Khanna, L. (2019). Synthesis, DFT studies, molecular docking, antimicrobial screening and UV fluorescence studies on ct-DNA for novel Schiff bases of 2-(1-aminobenzyl) benzimidazole. Heliyon, 5(10), e02596.
Singla, P., Luxami, V., & Paul, K. (2015). Triazine-benzimidazole hybrids: Anticancer activity, DNA interaction and dihydrofolate reductase inhibitors. Bioorganic & Medicinal Chemistry, 23(8), 1691-1700.
Singla, P., Luxami, V., & Paul, K. (2017). Quinazolinone-benzimidazole conjugates: Synthesis, characterization, dihydrofolate reductase inhibition, DNA and protein binding properties. Journal of Photochemistry and Photobiology B: Biology, 168, 156-164.
Soerjomataram, I., Lortet-Tieulent, J., Parkin, D. M., Ferlay, J., Mathers, C., Forman, D., & Bray, F. (2012). Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions. The Lancet, 380(9856), 1840-1850.
Song, B., Park, E. Y., Kim, K. J., & Ki, S. H. (2022). Repurposing of benzimidazole anthelmintic drugs as cancer therapeutics. Cancers, 14(19), 4601.
Sun, C., Chen, C., Xu, S., Wang, J., Zhu, Y., Kong, D., Tao, H., Jin, M., Zheng, P., & Zhu, W. (2016). Synthesis and anticancer activity of novel 4-morpholino-7, 8-dihydro-5H-thiopyrano [4, 3-d] pyrimidine derivatives bearing chromone moiety. Bioorganic & Medicinal Chemistry, 24(16), 3862-3869.
Tomczyk, M. D., & Walczak, K. Z. (2018). l, 8-Naphthalimide based DNA intercalators and anticancer agents. A systematic review from 2007 to 2017. European Journal of Medicinal Chemistry, (159), 159, 393-422.
Tsang, T., Peto, C., Jablons, D., & Alaoui, H. S. (2019). Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer. Google Patents.
Vos, S. M., Tretter, E. M., Schmidt, B. H., & Berger, J. M. (2011). All tangled up: How cells direct, manage and exploit topoisomerase function. Nature Reviews Molecular Cell Biology, 12(12), 827-841.
Waddell, A. R., Huang, H., & Liao, D. (2021). CBP/p300: Critical co-activators for nuclear steroid hormone receptors and emerging therapeutic targets in prostate and breast cancers. Cancers, 13(12), 2872.
Wang, L., Lin, X., Yu, L., & Sun, P. (2022). Romidepsin enhances the killing ability of NKG2D-CAR-T cells through enhanced expression of NKG2DL against ovarian cancer cells. Clinical and Experimental Obstetrics & Gynecology, 49(10), 227.
Wang, Y., Zhang, W.-X., & Xi, Z. (2020). Carbodiimide-based synthesis of N-heterocycles: Moving from two classical reactive sites to chemical bond breaking/forming reaction. Chemical Society Reviews, 49(16), 5810-5849.
Wang, Y.-N., Bheemanaboina, R. R. Y., Cai, G. X., & Zhou, C. H. (2018). Novel purine benzimidazoles as antimicrobial agents by regulating ROS generation and targeting clinically resistant Staphylococcus aureus DNA groove. Bioorganic & Medicinal Chemistry Letters, 28(9), 1621-1628.
Wang, Y.-T., Qin, Y. J., Yang, N., Zhang, Y. L., Liu, C. H., & Zhu, H. L. (2015). Synthesis, biological evaluation, and molecular docking studies of novel 1-benzene acyl-2-(1-methylindol-3-yl)-benzimidazole derivatives as potential tubulin polymerization inhibitors. European Journal of Medicinal Chemistry, 99, 125-137.
Wheate, N. J., Brodie, C. R., Collins, J. G., Kemp, S., & Aldrich-Wright, J. R. (2007). DNA intercalators in cancer therapy: Organic and inorganic drugs and their spectroscopic tools of analysis. Mini Reviews in Medicinal Chemistry, 7(6), 627-648.
Yadav, S., & Narasimhan, B. (2016). Perspectives of benzimidazole derivatives as anticancer agents in the new era. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 16(11), 1403-1425.
Yadav, S., Sinha, D., Singh, S. K., & Singh, V. K. (2012). Novel benzimidazole analogs as inhibitors of EGFR tyrosine kinase. Chemical Biology & Drug Design, 80(4), 625-630.
Yang, J. N. (2019). Targeting PBK in cancer: mechanisms and advances in clinical trials. MolCancer, 18(1), 26.
Zhang, X., Zhang, C., Tang, L., Lu, K., Zhao, H., Wu, W., & Jiang, Y. (2020). Synthesis and biological evaluation of piperidyl benzimidazole carboxamide derivatives as potent PARP-1 inhibitors and antitumor agents. Chinese Chemical Letters, 31(1), 136-140.
Zheng, F., Zhang, Y., Chen, S., Weng, X., Rao, Y., & Fang, H. (2020). Mechanism and current progress of poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomedicine & Pharmacotherapy, 123, 109661.
Zhou, W., Zhang, W., Peng, Y., Jiang, Z. H., Zhang, L., & Du, Z. (2020). Design, synthesis and anti-tumor activity of novel Benzimidazole-Chalcone hybrids as non-intercalative topoisomerase II catalytic inhibitors. Molecules, 25(14), 3180.
Zugazagoitia, J., Guedes, C., Ponce, S., Ferrer, I., Molina-Pinelo, S., & Paz-Ares, L. (2016). Current challenges in cancer treatment. Clinical Therapeutics, 38(7), 1551-1566.